
Claims

- 1. A method for treating inadequate myocardial function in a mammal comprising the administration to said mammal of a combination of (a) a compound comprising eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol synthesis or transfer inhibitor, in combination with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 70 mg/dl is achieved and whereby said treatment results in a rapid and enduring reduction in a symptom of inadequate myocardial function.
- 2. The method of claim 1, wherein said serum LDL concentration achieved is less than 55 mg/dl.
- 3. The method of claim 1, wherein said combination further comprises niacin.
 - 4. The method of claim 1, wherein said combination comprises aspirin.
- 5. The method of claim 1, wherein said reduction of a symptom of inadequate myocardial function occurs within 2 weeks.
- 6. The method of claim 1, wherein said reduction of a symptom of inadequate myocardial function occurs with 1 week.



- 8. The method of claim 1, wherein said compound is a marine lipid.
- 9. The method of claim 8, wherein said marine lipid is a fish oil.
- 10. The method of claim 1, wherein said cholesterol synthesis or transfer inhibitor is administered at greater than or equal to 10 mg/day.
- 11. The method of claim 1, wherein said cholesterol synthesis or transfer inhibitor acts by inhibiting hydroxymethylglutarate (HMG) CoA reductase.
- 12. The method of claim 1, wherein said cholesterol synthesis or transfer inhibitor is chosen from the group consisting of simvastatin, lovastatin, fluvastatin, and pravastatin.
- 13. The method of claim 3, wherein said niacin is administered at between 0.5 3 g/day.
- 14. The method of claim 4, wherein said aspirin is administered at greater than or equal to 80 mg/day.

- 15. The method of claim 1, wherein said method further comprises administering to said mammal a bile acid sequestrant.
- 16. The method of claim 15, wherein said sequestrant is administered at between 5 20 g/day.
- 17. The method of claim 15, wherein said sequestrant is chosen from cholestyramine or colestipol.
- 18. A medication comprising (a) a compound comprising eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol synthesis or transfer inhibitor.
- 19. The medication of claim 18, wherein said compound comprising eicosapentaeneoic acid or docosahexaeneoic acid is to be administered at greater than or equal to 5 g/day.
- 20. The medication of claim 18, wherein said compound comprising eicosapentaeneoic acid or docosahexaeneoic acid is a marine lipid.
 - 21. The medication of claim 20, wherein said marine lipid is a fish oil.
- 22. The medication of claim 18, wherein said cholesterol synthesis or transfer inhibitor is to be administered at greater than or equal to 10 mg/day.

- 23. The medication of claim 18, wherein said cholesterol synthesis or transfer inhibitor acts by inhibiting HMG CoA reductase.
- 24. The medication of claim 18, wherein said cholesterol synthesis or transfer inhibitor is chosen from the group consisting of simvastatin, lovastatin, fluvastatin, and pravastatin.
- 25. The medication of claim 18, wherein said medication further comprises niacin.
- 26. The medication of claim 25, wherein said niacin is to be administered at between 0.5 3 g/day.
- 27. The medication of claim 18, wherein said medication further comprises aspirin.
- 28. The medication of claim 27, wherein said aspirin is administered at greater than or equal to 80 mg/day.
- 29. The medication of claim 18, wherein said medication further comprises a bile acid sequestrant.
- 30. The medication of claim 29, wherein said sequestrant is to be administered at between 5 20 g/day.

- 31. The medication of claim 29, wherein said sequestrant is chosen from cholestyramine or colestipol.
- 32. The medication of claim 18, wherein said medication is used to treat inadequate myocardial function.
- 33. The medication of claim 18, wherein said medication reduces a coronary artery stenosis by at least 20%.
- 34. The medication of claim 18, wherein said medication restores blood flow to infarcted myocardium.
- 35. The medication of claim 18, wherein said medication improves myocardial perfusion without invasive revascularization of a coronary artery.
- 36. A method for reducing a coronary artery stenosis by at least 20% in a mammal, comprising the administration to said mammal of a cholesterol-lowering therapeutic combined with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 75 mg/dl is achieved.

- 37. A method for restoring blood flow to infarcted myocardium in a mammal, comprising the administration to said mammal of (a) a compound comprising eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 75 mg/dl is achieved.
- 38. A method for improving myocardial function without invasive revascularization of a coronary artery in a mammal, said method comprising the administration to said mammal of (a) a compound comprising eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 75 mg/dl is achieved.
- 39. The method of claim 38, wherein said method eliminates the need for physical manipulation of a coronary artery.
- 40. The method of claim 38, wherein said invasive revascularization comprises coronary bypass grafting or angioplasty.
- 41. The method of claim 38, wherein said method prevents coronary artery disease recurrence for greater than 5 years.
- 42. The method of claim 41, wherein said method prevents coronary artery disease recurrence for greater than 10 years.

- 43. The method of claim 38, wherein said improvement in myocardial function occurs within 4 weeks.
- 44. The method of claim 43, wherein said improvement in myocardial function occurs within 1 week.
- 45. A method for preventing a heart attack in a mammal at high risk for heart attack due to coronary artery disease, said method comprising the administration to said mammal of (a) a compound comprising eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol synthesis or transfer inhibitor, combined with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 75 mg/dl is achieved.
- 46. The method of claim 45, wherein said compound comprising eicosapentaeneoic acid or docosahexaeneoic acid is administered at greater than or equal to 5 g/day.
- 47. The method of claim 45, wherein said compound comprising eicosapentaeneoic acid or docosahexaeneoic acid is a marine lipid.
- 48. The method of claim 45, wherein said cholesterol synthesis or transfer inhibitor is chosen from the group consisting of simvastatin, lovastatin, fluvastatin, and pravastatin.

- 49. The methods of claims 36, 37, 38, or 45, wherein said serum LDL concentration achieved is less than 55 mg/dl.
- 50. The method of claim 45, wherein a bile acid sequestrant is further administered to said mammal.
- 51. The method of claim 45, wherein niacin is further administered to said mammal.
- 52. The method of claim 45, wherein aspirin is further administered to said mammal.
- 53. A method for reducing mortality due to an adverse cardiovascular event, said method comprising the administration to said mammal of (a) a compound comprising eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 75 mg/dl is achieved.
- 54. The method of claim 53, wherein said serum LDL concentration achieved is less than 55 mg/dl.